Anita C. Bellail
Biochemistry, Genetics and Molecular Biology · Indiana University
Cell death mechanisms and regulationinterferon and immune responsesUbiquitin and proteasome pathwaysCancer-related Molecular PathwaysCancer, Hypoxia, and Metabolism
Publications
55
Citations
3,772
Est. group size
—
Recurring co-author estimate
Active years
26
Publishing since 2000
Publication cadence
Publications per year over the last 10 years — averaging 2.4/year recently
Recent publications
- Synergistic Antitumor Activity of SUMO1 degrader and Oxaliplatin through G6PD Inhibition in Colorectal Cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Supplementary Figures 1-11, Methods from A20 Ubiquitin Ligase–Mediated Polyubiquitination of RIP1 Inhibits Caspase-8 Cleavage and TRAIL-Induced Apoptosis in Glioblastoma
2023
- Supplementary Figures 1-11, Methods from A20 Ubiquitin Ligase–Mediated Polyubiquitination of RIP1 Inhibits Caspase-8 Cleavage and TRAIL-Induced Apoptosis in Glioblastoma
2023
- Data from A20 Ubiquitin Ligase–Mediated Polyubiquitination of RIP1 Inhibits Caspase-8 Cleavage and TRAIL-Induced Apoptosis in Glioblastoma
2023
- Data from A20 Ubiquitin Ligase–Mediated Polyubiquitination of RIP1 Inhibits Caspase-8 Cleavage and TRAIL-Induced Apoptosis in Glioblastoma
2023
- Molecular glue degraders enhance CAPRIN1-dependent lysosomal degradation of APP in Alzheimer’s disease
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- SUMO1 degrader induces ER stress and ROS accumulation through deSUMOylation of TCF4 and inhibition of its transcription of StarD7 in colon cancer
Molecular Carcinogenesis · 2023
- Data from Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
2023
- Supplementary Figures 1-15 from Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
2023
- Supplementary Figures 1-15 from Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
2023
- Cover Image, Volume 62, Issue 9
Molecular Carcinogenesis · 2023
- Data from Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment
2023
- Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor‐initiating cells
Brain Pathology · 2021
- PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway
Science Advances · 2021
- Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumors
Science Translational Medicine · 2021
Publishes in
- Molecular Carcinogenesis×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Science Translational Medicine×1
- Brain Pathology×1
- Science Advances×1
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile